Sana Health Clears a Major Milestone in the Fight Against Chronic Pain

Sana Health has just secured the world’s first regulatory clearance for an audiovisual neuromodulation system targeting neuropathic pain, with Health Canada approval already in hand and a pending FDA decision expected in January. This milestone validates a decade‑long effort to replace drugs like Lyrica and Gabapentin, which carry weight gain and tolerance issues, with a non‑pharmacologic, at‑home therapy. By achieving the first ever approval for this modality, Sana positions itself at the forefront of pain‑tech innovation and opens pathways for broader reimbursement discussions in North America.

Clinical data reinforce the device’s disruptive potential. In a Department of Defense‑funded pilot, combining the neuromodulation unit with standard prolonged‑exposure therapy produced a three‑fold improvement in PTSD symptom scores compared with therapy alone. Parallel studies in Israeli veterans reported clinically meaningful drops in both PTSD and chronic‑pain metrics, while a pivotal trial showed an 80% reduction in opioid and gabapentinoid consumption despite participants being instructed not to alter medication regimens. These outcomes not only demonstrate therapeutic efficacy but also attract strategic buyers—Canada, Israel, and the U.S. VA—whose adoption could trigger breakthrough status prioritization from CMS, accelerating coding and coverage.

Beyond immediate results, Sana’s growth strategy hinges on a disciplined “data ladder” approach: rapid, low‑cost feasibility studies that feed into increasingly rigorous trials, culminating in large‑scale RCTs. The upcoming device iteration replaces conventional LEDs with a laser‑based photoplethysmography sensor, eliminating skin‑tone bias and enhancing signal fidelity for diverse populations, especially those served by the military and veteran health systems. By embedding the technology within a multimodal care basket—paired with digital CBT, VR, and selective pharmacotherapy—Sana aims to reshape chronic pain and mental‑health treatment models, delivering scalable, medication‑sparing solutions worldwide.